An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Unloading with Impella for 30 Minutes Before PCI Associated with Reduced Infarct Size in STEMI Patients
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Negative)
Tags
Rhea-AI Summary
A new analysis from the STEMI DTU pilot trial reveals a significant reduction in heart muscle damage in STEMI patients who underwent 30 minutes of left ventricular unloading with Impella CP before percutaneous coronary intervention (PCI). Results showed a lower infarct size normalized to the area at risk (47±16 vs. 60±16, p=0.02), representing a 22% relative and 13% absolute reduction. These findings, presented by Dr. Navin K. Kapur at the 2022 TCT conference, suggest that this approach could improve outcomes by minimizing myocardial damage and reducing heart failure risk.
Positive
Significant reduction of infarct size observed in delayed PCI group (47±16 vs. 60±16, p=0.02).
22% relative and 13% absolute reduction in infarct size normalized to area at risk.
Study suggests 30 minutes of LV unloading could improve patient outcomes post-STEMI.
Negative
None.
BOSTON--(BUSINESS WIRE)--
Results of a new per-protocol analysis of the ST-segment Elevation Myocardial Infarction Door-To-Unload (STEMI DTU) pilot trial data show significantly reduced infarct size in patients who received left ventricular (LV) unloading with Impella CP for 30 minutes prior to their percutaneous coronary intervention (PCI) compared to patients who received LV unloading followed by immediate PCI. The data were presented today during the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference in Boston by Navin K. Kapur, MD, executive director of the Cardiovascular Center for Research and Innovation (CVCRI) at Tufts Medical Center and the principal investigator for the STEMI DTU pivotal randomized controlled trial.
The STEMI DTU pilot trial demonstrated for the first time that LV unloading using the Impella CP® heart pump with a 30-minute delay before reperfusion is safe and feasible. (Graphic: Business Wire)
The new analysis compared infarct size in 32 patients from the STEMI DTU pilot trial who met all inclusion and exclusion criteria. All patients experienced an anterior STEMI and completed one of two treatment protocols – LV unloading with Impella CP followed by immediate PCI (n=15) or LV unloading with Impella CP for 30 minutes prior to delayed PCI (n=17). Cardiac magnetic resonance (CMR) imaging performed three-to-five days after PCI was used to determine infarct size (IS) normalized to the area at risk (AAR). Results showed that the infarct size normalized to the area at risk was significantly lower in the delayed PCI group compared to the immediate PCI group (IS/AAR: 47±16 vs. 60±16, p=0.02), which translates to a 22% relative and 13% absolute reduction in IS/AAR.
“Results from this analysis are early, but promising, indicating that in STEMI patients, unloading the left ventricle with Impella CP for 30 minutes and delaying PCI could potentially help improve patient outcomes by reducing damage to the heart muscle and helping prevent heart failure,” said Dr. Kapur.
Myocardial damage can lead to heart failure. Every 5% increase in infarct size is associated with a 20% increase in relative hazard for all-cause mortality or hospitalization for heart failure within one year after a primary PCI(JACC, 2016). Coronary artery disease is the number one cause of death in the United States and 47% of women and 36% of men over the age of 45 will die within five years of their first heart attack(Circulation, 2019).
The STEMI DTU pilot study demonstrated for the first time that LV unloading using Impella CP with a 30-minute delay before reperfusion via PCI is feasible, safe and not associated with an increase in infarct size. The pilot study led to the STEMI DTU pivotal randomized controlled trial, which began in 2019 and is actively enrolling patients. The pivotal trial is testing the hypothesis that compared to PCI alone, LV unloading for 30 minutes prior to PCI can reduce myocardial damage and future heart failure-related events due to a heart attack.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® with SmartAssist® are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.
Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD®, and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
Impella heart pumps are not FDA approved for use in STEMI patients without cardiogenic shock.
ABOUT ABIOMED Based in Danvers, Massachusetts, USA, Abiomed (Nasdaq: ABMD) is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest and recover by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Media Contact:
Jenny Leary Associate Director, U.S. Communications +1 (978) 882-8491
jleary@abiomed.com
Investor Contact:
Todd Trapp Executive Vice President and Chief Financial Officer
+1 (978) 646-1680
ttrapp@abiomed.com
Source: Abiomed, Inc.
FAQ
What were the results of the STEMI DTU pilot trial presented by Abiomed?
The trial showed that left ventricular unloading with Impella CP for 30 minutes before PCI significantly reduced infarct size compared to immediate PCI.
What does the reduced infarct size mean for patients?
A reduced infarct size can lead to better heart recovery and lower risk of heart failure after a heart attack.
Who presented the findings of the STEMI DTU trial?
Dr. Navin K. Kapur presented the findings at the 2022 Transcatheter Cardiovascular Therapeutics (TCT) conference.
What is the significance of the 22% reduction in infarct size?
The 22% relative reduction in infarct size may correlate with improved long-term heart health and lower mortality risks for patients.
When did the STEMI DTU pivotal randomized controlled trial begin?
The pivotal trial began in 2019 and is actively enrolling patients.
